Amneal Pharmaceuticals, Inc. (AMRX) Debt by Year
Amneal Pharmaceuticals, Inc. carried $2.6B in long-term debt against $282.0M in cash and equivalents at the end of fiscal year 2025. This represents an increase of 18.7% from the prior fiscal year. The table below carries 10 fiscal years, from 2016 to 2025, and the quarters Amneal Pharmaceuticals, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
AMRX Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K |
|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $2.6B+18.7% | $2.2B-9.4% | $2.4B-7.9% | $2.6B-3.3% | $2.7B-2.0% | $2.7B+4.8% | $2.6B-0.8% | $2.6B+94.1% | $1.4B | N/A |
| Cash & Equivalents | $282.0M+155.1% | $110.6M+20.8% | $91.5M+252.4% | $26.0M-89.5% | $247.8M-27.4% | $341.4M+125.8% | $151.2M-29.1% | $213.4M+187.7% | $74.2M+171.0% | $27.4M |
AMRX Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $2.6B+19.5% | $2.6B+19.1% | $2.6B+18.7% | $2.6B+18.3% | $2.1B-1.4% | $2.2B-9.4% | $2.2B-9.4% | $2.2B-14.6% | $2.2B-14.6% | $2.4B-7.2% | $2.4B-7.9% | $2.5B-2.5% |
| Cash & Equivalents | $127.6M+78.4% | $197.7M+234.0% | $282.0M+155.1% | $201.2M+171.9% | $71.5M+63.5% | $59.2M+27.2% | $110.6M+20.8% | $74.0M-14.9% | $43.8M-59.9% | $46.5M-67.8% | $91.5M+252.4% | $86.9M-0.5% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Amneal Pharmaceuticals, Inc. financials
Frequently Asked Questions
What was Amneal Pharmaceuticals, Inc.'s long-term debt in fiscal year 2025?
Amneal Pharmaceuticals, Inc. carried $2.6B in long-term debt against $282.0M in cash and equivalents at the end of fiscal year 2025.
How fast is Amneal Pharmaceuticals, Inc.'s long-term debt growing?
Amneal Pharmaceuticals, Inc. (AMRX) long-term debt rose by 18.7% year over year, from $2.2B to $2.6B in fiscal year 2025.
What was Amneal Pharmaceuticals, Inc.'s long-term debt in the most recent quarter?
Amneal Pharmaceuticals, Inc. (AMRX) reported $2.6B in long-term debt in Q2 2026. This represents an increase of 19.5% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Amneal Pharmaceuticals, Inc. (AMRX) reported on that line in every period on record.